Ashenagar, M.S.; Matsumoto, A.; Sakai, H.; Tokiya, M.; Hara, M.; Hirota, Y.
Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines 2022, 10, 487.
https://doi.org/10.3390/vaccines10040487
AMA Style
Ashenagar MS, Matsumoto A, Sakai H, Tokiya M, Hara M, Hirota Y.
Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines. 2022; 10(4):487.
https://doi.org/10.3390/vaccines10040487
Chicago/Turabian Style
Ashenagar, Mohammad Said, Akiko Matsumoto, Hironori Sakai, Mikiko Tokiya, Megumi Hara, and Yoshio Hirota.
2022. "Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine" Vaccines 10, no. 4: 487.
https://doi.org/10.3390/vaccines10040487
APA Style
Ashenagar, M. S., Matsumoto, A., Sakai, H., Tokiya, M., Hara, M., & Hirota, Y.
(2022). Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines, 10(4), 487.
https://doi.org/10.3390/vaccines10040487